ATE434616T1 - Aktivator des peroxisomproliferator-aktivierten rezeptors delta - Google Patents

Aktivator des peroxisomproliferator-aktivierten rezeptors delta

Info

Publication number
ATE434616T1
ATE434616T1 AT02801515T AT02801515T ATE434616T1 AT E434616 T1 ATE434616 T1 AT E434616T1 AT 02801515 T AT02801515 T AT 02801515T AT 02801515 T AT02801515 T AT 02801515T AT E434616 T1 ATE434616 T1 AT E434616T1
Authority
AT
Austria
Prior art keywords
activated receptor
peroxisome proliferator
receptor delta
alkyl
delta activator
Prior art date
Application number
AT02801515T
Other languages
English (en)
Inventor
Shogo Sakuma
Tomio Yamakawa
Takashi Kanda
Seiichiro Masui
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Application granted granted Critical
Publication of ATE434616T1 publication Critical patent/ATE434616T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02801515T 2001-10-12 2002-10-09 Aktivator des peroxisomproliferator-aktivierten rezeptors delta ATE434616T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001315694 2001-10-12
PCT/JP2002/010472 WO2003033493A1 (en) 2001-10-12 2002-10-09 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ

Publications (1)

Publication Number Publication Date
ATE434616T1 true ATE434616T1 (de) 2009-07-15

Family

ID=19133818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801515T ATE434616T1 (de) 2001-10-12 2002-10-09 Aktivator des peroxisomproliferator-aktivierten rezeptors delta

Country Status (17)

Country Link
US (2) US7119104B2 (de)
EP (1) EP1445258B1 (de)
JP (1) JP4276074B2 (de)
KR (1) KR100933652B1 (de)
CN (1) CN1293076C (de)
AT (1) ATE434616T1 (de)
AU (1) AU2002335231B2 (de)
BR (1) BRPI0213243B8 (de)
CA (1) CA2463569C (de)
CY (1) CY1110355T1 (de)
DE (1) DE60232739D1 (de)
DK (1) DK1445258T3 (de)
ES (1) ES2326411T3 (de)
IL (2) IL161351A0 (de)
MX (1) MXPA04003398A (de)
PT (1) PT1445258E (de)
WO (1) WO2003033493A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1445258E (pt) * 2001-10-12 2009-07-02 Nippon Chemiphar Co Activador para o receptor delta activado por proliferador de peroxissoma
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
SI1667964T1 (sl) 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP1745014B1 (de) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Neue verbindungen, deren herstellung und verwendung
CN101018790A (zh) * 2004-09-11 2007-08-15 塞诺菲-安万特德国有限公司 7－氮杂吲哚以及其用作ppar激动剂的应用
US7833513B2 (en) * 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
AU2006265172B2 (en) 2005-06-30 2011-09-15 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
CA2614315A1 (en) * 2005-07-06 2007-01-11 Nippon Chemiphar Co., Ltd. Activator of peroxisome proliferator activated receptor d
JP2009509932A (ja) * 2005-09-07 2009-03-12 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
NZ572268A (en) * 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2008016175A1 (en) * 2006-08-03 2008-02-07 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor
JP5247686B2 (ja) 2007-05-21 2013-07-24 千寿製薬株式会社 ＰＰＡＲδアゴニスト含有医薬
WO2008154023A1 (en) * 2007-06-11 2008-12-18 Cerenis Therapeutics S.A. Novel uses of ppar delta agonists
BRPI0911197A2 (pt) 2008-04-15 2015-10-13 Nippon Chemiphar Co composto, ativador de receptor ativado pelo proliferador de peroxissoma, e, medicamento para o tratamento e /ou profilaxia de uma doença.
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102724978A (zh) * 2009-08-14 2012-10-10 塞伦尼斯治疗公司 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
JP2013006769A (ja) * 2009-10-08 2013-01-10 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
WO2014119642A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 安定な水性液剤
MX368621B (es) 2013-01-31 2019-10-08 Senju Pharma Co Solucion acuosa clara.
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20190255022A1 (en) * 2016-05-12 2019-08-22 Nippon Chemiphar Co., Ltd. Wound-healing agent
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018174983A2 (en) * 2016-12-30 2018-09-27 Nuscale Power, Llc Control rod drive mechanism (crdm) with remote disconnect mechanism
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN113912547B (zh) 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
CN115215856B (zh) * 2022-08-19 2024-10-11 沈阳药科大学 一种PPARδ激动剂福那德帕及其中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5089541A (en) * 1990-11-23 1992-02-18 Shell Oil Company Removal of hydrogenation catalyst from polymer solutions by contact with activated carbon
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
US6043264A (en) 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
CA2171702A1 (en) 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
WO1996035688A1 (en) 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hypoglycemic agent
KR19990076788A (ko) 1996-01-22 1999-10-15 후지야마 아키라 티아졸릴벤조푸란 유도체 및 그를 함유하는 약제학적 조성물
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
ES2320181T3 (es) 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2002016332A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
IL160304A0 (en) * 2001-08-10 2004-07-25 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta
PT1445258E (pt) * 2001-10-12 2009-07-02 Nippon Chemiphar Co Activador para o receptor delta activado por proliferador de peroxissoma
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
KR20040053164A (ko) 2004-06-23
KR100933652B1 (ko) 2009-12-23
US20070027196A1 (en) 2007-02-01
CY1110355T1 (el) 2015-04-29
US7119104B2 (en) 2006-10-10
MXPA04003398A (es) 2004-11-22
BRPI0213243B8 (pt) 2021-05-25
DK1445258T3 (da) 2009-10-12
DE60232739D1 (de) 2009-08-06
BR0213243A (pt) 2005-01-04
BRPI0213243B1 (pt) 2021-03-16
US7402597B2 (en) 2008-07-22
CA2463569A1 (en) 2003-04-24
JP4276074B2 (ja) 2009-06-10
EP1445258A4 (de) 2006-01-04
PT1445258E (pt) 2009-07-02
EP1445258A1 (de) 2004-08-11
CA2463569C (en) 2012-05-15
AU2002335231B2 (en) 2008-05-08
EP1445258B1 (de) 2009-06-24
JPWO2003033493A1 (ja) 2005-02-03
CN1293076C (zh) 2007-01-03
ES2326411T3 (es) 2009-10-09
US20050096363A1 (en) 2005-05-05
WO2003033493A1 (en) 2003-04-24
IL161351A (en) 2012-12-31
CN1568323A (zh) 2005-01-19
IL161351A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
ATE434616T1 (de) Aktivator des peroxisomproliferator-aktivierten rezeptors delta
BR0211844A (pt) Composto e ativador de receptor delta ativado por proliferador e peroxissoma
ATE542805T1 (de) Ppar-delta aktivatoren
ATE415160T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
ID20564A (id) Senyawa-senyawa heterosiklik yang mempunyai aktifitas anti-diabetes, pembuatannya dan penggunaannya (pecahan dari p-950588)
EP1203768A4 (de) Isoxazolin derivate und herbizide, die diese als aktiven bestandteil enthalten
DE60315603D1 (de) Modulatoren von peroxisome proliferator-aktivierten rezeptoren
DK0378518T3 (da) Adenosinderivater med farmaceutisk aktivitet som antihypertensiva
ES2145743T3 (es) Compuesto de anillo condensado benzoxa, su produccion y composicion farmaceutica que lo contiene.
FI923033A0 (fi) N-fenyltioureaderivat och farmaceutisk anvaendning av dem.
NO20042010L (no) 4-imidazolin-2-on forbindelser
DE60015390D1 (de) Antidiabetische thiazolidindione und ihre herstellung
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
CA2371827A1 (en) Amide compounds for the potentiation of cholinergic activity
DE69830600D1 (de) Anilidverbindungen und medikamente, die diese enthalten
MXPA03002442A (es) Derivados tiazol de 2-metoxiimino-2-(piridiniloximetil)-fenil-acetamidas utiles como fungicidas.
DE69828087D1 (de) Aminderivate
DE60211686D1 (de) Pkb-3564-substanz mit die gefässneubildung hemmender wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1445258

Country of ref document: EP